Branimir I. Sikic, M. D.

Publication Details

  • PRELIMINARY-OBSERVATIONS OF INTRAPERITONEAL CARBOPLATIN PHARMACOKINETICS DURING A PHASE-I STUDY OF THE NORTHERN-CALIFORNIA-ONCOLOGY-GROUP CANCER CHEMOTHERAPY AND PHARMACOLOGY DeGregorio, M. W., Lum, B. L., Holleran, W. M., WILBUR, B. J., Sikic, B. I. 1986; 18 (3): 235-238

    Abstract:

    The pharmacokinetic behavior of carboplatin administered by the i.p. route at a dose of 200 mg/m2 was studied during five courses of therapy in four patients with ovarian cancer. A regional pharmacologic advantage was noted with carboplatin administered by this route, with peak peritoneal fluid concentrations 18-fold those in plasma, and area under the curve (AUC) for the peritoneum showing a 18-fold and 6-fold increase over plasma AUC at 4 and 24 h, respectively. The mean residence time of total platinum in the peritoneum was 4.7 h. Approximately 10% and 40% of plasma platinum was protein bound at 4 and 24 h after treatment, respectively, whereas peritoneal fluid platinum showed minimal protein binding. Peak plasma platinum levels were comparable to those recorded in previous studies with i.v. doses of carboplatin. Peritoneal clearance of carboplatin in these four patients appeared to be less than that previously reported for cisplatin. Further studies are in progress with higher doses of i.p. carboplatin.

    View details for Web of Science ID A1986F914200010

    View details for PubMedID 3542268

Stanford Medicine Resources:

Footer Links: